Actinium Pharmaceuticals reports results from Phase 3 SIERRA Trial of Iomab-B

Actinium Pharmaceuticals highlighted data from multiple abstracts that were presented at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting being held June 8 – 11, 2024, in Toronto, Canada. The presentations featured results from the Phase 3 SIERRA trial of Iomab-B, a CD45 targeting ARC with the Iodine-131 payload, intended for conditioning to prepare patients with active relapsed or refractory acute myeloid leukemia for a potentially curative bone marrow transplant. The Phase 3 SIERRA trial enrolled 153 r/r AML patients. Iomab-B achieved the primary endpoint of durable Complete Remission with high statistical significance. Additionally, Actinium’s novel linker technology was highlighted in a presentation demonstrating high tumor uptake and in vivo stability in preclinical models with significantly lower kidney and liver uptake compared to standard DOTA linkers.